Abstract
In locally advanced rectal cancer (LARC), some prior studies have predicted survival outcomes with hypoxic markers, especially glucose transporter-1 (GLUT-1). This study aimed to investigate the prognostic role of GLUT-1 in LARC using the data of 208 patients with clinical T3–4 stage and/or node-positive rectal adenocarcinoma, all of whom underwent neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
